Medical - Devices
Compare Stocks
5 / 10Stock Comparison
INMD vs AEYE vs STAA vs NVCR vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Software - Application
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Instruments & Supplies
INMD vs AEYE vs STAA vs NVCR vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Software - Application | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $882M | $100M | $1.35B | $1.92B | $161.07B |
| Revenue (TTM) | $375M | $40M | $239M | $674M | $10.58B |
| Net Income (TTM) | $87M | $-3M | $-80M | $-173M | $2.98B |
| Gross Margin | 77.8% | 78.3% | 75.6% | 75.2% | 66.3% |
| Operating Margin | 21.3% | -7.9% | -33.3% | -27.2% | 30.5% |
| Forward P/E | 9.6x | — | 70.2x | — | 43.8x |
| Total Debt | $13M | $721K | $38M | $290M | $303M |
| Cash & Equiv. | $303M | $5M | $153M | $103M | $3.37B |
INMD vs AEYE vs STAA vs NVCR vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| InMode Ltd. (INMD) | 100 | 95.0 | -5.0% |
| AudioEye, Inc. (AEYE) | 100 | 95.5 | -4.5% |
| STAAR Surgical Comp… (STAA) | 100 | 70.3 | -29.7% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
| Intuitive Surgical,… (ISRG) | 100 | 234.6 | +134.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INMD vs AEYE vs STAA vs NVCR vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INMD ranks third and is worth considering specifically for valuation efficiency.
- PEG 0.97 vs ISRG's 2.01
- Lower P/E (9.6x vs 43.8x), PEG 0.97 vs 2.01
AEYE lags the leaders in this set but could rank higher in a more targeted comparison.
STAA is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- beta 0.54
- Beta 0.54, current ratio 4.55x
- Beta 0.54 vs AEYE's 2.29, lower leverage
- +40.3% vs AEYE's -27.9%
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
ISRG carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs STAA's 273.7%
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
- 20.5% revenue growth vs STAA's -23.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs STAA's -23.7% | |
| Value | Lower P/E (9.6x vs 43.8x), PEG 0.97 vs 2.01 | |
| Quality / Margins | 28.2% margin vs STAA's -33.6% | |
| Stability / Safety | Beta 0.54 vs AEYE's 2.29, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +40.3% vs AEYE's -27.9% | |
| Efficiency (ROA) | 14.8% ROA vs STAA's -17.8%, ROIC 15.0% vs -13.2% |
INMD vs AEYE vs STAA vs NVCR vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
INMD vs AEYE vs STAA vs NVCR vs ISRG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
INMD leads 1 • STAA leads 1 • AEYE leads 0 • NVCR leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 262.5x AEYE's $40M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to STAA's -33.6%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $375M | $40M | $239M | $674M | $10.6B |
| EBITDAEarnings before interest/tax | $81M | -$504,000 | -$71M | -$165M | $3.8B |
| Net IncomeAfter-tax profit | $87M | -$3M | -$80M | -$173M | $3.0B |
| Free Cash FlowCash after capex | $91M | $2M | -$34M | -$48M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +77.8% | +78.3% | +75.6% | +75.2% | +66.3% |
| Operating MarginEBIT ÷ Revenue | +21.3% | -7.9% | -33.3% | -27.2% | +30.5% |
| Net MarginNet income ÷ Revenue | +23.3% | -7.6% | -33.6% | -25.7% | +28.2% |
| FCF MarginFCF ÷ Revenue | +24.2% | +5.5% | -14.4% | -7.1% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.3% | +7.9% | +18.1% | +12.3% | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -30.8% | +29.0% | +47.8% | -100.0% | +18.8% |
Valuation Metrics
INMD leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 9.7x trailing earnings, INMD trades at a 83% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), INMD offers better value at 0.98x vs ISRG's 2.65x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $882M | $100M | $1.3B | $1.9B | $161.1B |
| Enterprise ValueMkt cap + debt − cash | $593M | $96M | $1.2B | $2.1B | $158.0B |
| Trailing P/EPrice ÷ TTM EPS | 9.73x | -32.36x | -16.84x | -13.80x | 57.62x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.64x | — | 70.16x | — | 43.84x |
| PEG RatioP/E ÷ EPS growth rate | 0.98x | — | — | — | 2.65x |
| EV / EBITDAEnterprise value multiple | 6.88x | — | — | — | 43.62x |
| Price / SalesMarket cap ÷ Revenue | 2.38x | 2.49x | 5.63x | 2.92x | 16.00x |
| Price / BookPrice ÷ Book value/share | 1.33x | 20.91x | 3.93x | 5.51x | 9.17x |
| Price / FCFMarket cap ÷ FCF | 10.46x | — | — | — | 64.67x |
Profitability & Efficiency
ISRG leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-51 for NVCR. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs STAA's 1/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +13.3% | -47.8% | -23.2% | -50.8% | +16.9% |
| ROA (TTM)Return on assets | +11.8% | -9.5% | -17.8% | -16.5% | +14.8% |
| ROICReturn on invested capital | +13.5% | -42.4% | -13.2% | -16.4% | +15.0% |
| ROCEReturn on capital employed | +12.1% | -17.7% | -11.2% | -28.9% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 1 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.02x | 0.15x | 0.11x | 0.85x | 0.02x |
| Net DebtTotal debt minus cash | -$289M | -$5M | -$115M | $187M | -$3.1B |
| Cash & Equiv.Liquid assets | $303M | $5M | $153M | $103M | $3.4B |
| Total DebtShort + long-term debt | $13M | $721,000 | $38M | $290M | $303M |
| Interest CoverageEBIT ÷ Interest expense | — | -2.79x | — | -96.80x | — |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, STAA leads with a +40.3% total return vs AEYE's -27.9%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -5.9% | -18.7% | +15.6% | +28.3% | -19.3% |
| 1-Year ReturnPast 12 months | -2.1% | -27.9% | +40.3% | +1.1% | -15.4% |
| 3-Year ReturnCumulative with dividends | -60.2% | +20.6% | -59.7% | -75.7% | +49.6% |
| 5-Year ReturnCumulative with dividends | -63.9% | -60.2% | -80.2% | -91.3% | +58.7% |
| 10-Year ReturnCumulative with dividends | +105.0% | +102.2% | +273.7% | +30.3% | +554.2% |
| CAGR (3Y)Annualised 3-year return | -26.4% | +6.4% | -26.1% | -37.6% | +14.4% |
Risk & Volatility
STAA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
STAA is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than AEYE's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. STAA currently trades 88.5% from its 52-week high vs AEYE's 49.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.04x | 2.29x | 0.54x | 2.20x | 1.02x |
| 52-Week HighHighest price in past year | $16.74 | $16.39 | $30.81 | $20.06 | $603.88 |
| 52-Week LowLowest price in past year | $12.72 | $5.31 | $15.64 | $9.82 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +83.2% | +49.4% | +88.5% | +83.9% | +75.1% |
| RSI (14)Momentum oscillator 0–100 | 39.8 | 61.3 | 70.0 | 69.8 | 42.4 |
| Avg Volume (50D)Average daily shares traded | 804K | 194K | 1.2M | 1.5M | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: INMD as "Buy", STAA as "Hold", NVCR as "Buy", ISRG as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -15.9% for STAA (target: $23).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $16.00 | — | $22.95 | $33.50 | $622.60 |
| # AnalystsCovering analysts | 11 | — | 15 | 15 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +14.5% | 0.0% | +0.5% | 0.0% | +1.4% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). INMD leads in 1 (Valuation Metrics).
INMD vs AEYE vs STAA vs NVCR vs ISRG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INMD or AEYE or STAA or NVCR or ISRG a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -23. 7% for STAAR Surgical Company (STAA). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate InMode Ltd. (INMD) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INMD or AEYE or STAA or NVCR or ISRG?
On trailing P/E, InMode Ltd.
(INMD) is the cheapest at 9. 7x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, InMode Ltd. is actually cheaper at 9. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: InMode Ltd. wins at 0. 97x versus Intuitive Surgical, Inc. 's 2. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — INMD or AEYE or STAA or NVCR or ISRG?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INMD or AEYE or STAA or NVCR or ISRG?
By beta (market sensitivity over 5 years), STAAR Surgical Company (STAA) is the lower-risk stock at 0.
54β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 322% more volatile than STAA relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — INMD or AEYE or STAA or NVCR or ISRG?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -23. 7% for STAAR Surgical Company (STAA). On earnings-per-share growth, the picture is similar: AudioEye, Inc. grew EPS 30. 6% year-over-year, compared to -295. 1% for STAAR Surgical Company. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INMD or AEYE or STAA or NVCR or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -33. 6% for STAAR Surgical Company — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INMD or AEYE or STAA or NVCR or ISRG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, InMode Ltd. (INMD) is the more undervalued stock at a PEG of 0. 97x versus Intuitive Surgical, Inc. 's 2. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, InMode Ltd. (INMD) trades at 9. 6x forward P/E versus 70. 2x for STAAR Surgical Company — 60. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — INMD or AEYE or STAA or NVCR or ISRG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is INMD or AEYE or STAA or NVCR or ISRG better for a retirement portfolio?
For long-horizon retirement investors, STAAR Surgical Company (STAA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
54), +273. 7% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (STAA: +273. 7%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INMD and AEYE and STAA and NVCR and ISRG?
These companies operate in different sectors (INMD (Healthcare) and AEYE (Technology) and STAA (Healthcare) and NVCR (Healthcare) and ISRG (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: INMD is a small-cap deep-value stock; AEYE is a small-cap quality compounder stock; STAA is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.